eoadjuvant Radiotherapy in breast Cancer, A study on the optimal sequencing of radiation in breast cancer. - NeoORB

All India Institute of Medical Sciences, Jodhpur0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1)Eligibility for NACT:
•Patients with inoperable breast cancer:
•a)Bulky or matted cN2 axillary nodes
•b)cN3 nodal disease
•c)cT4 tumors(Inflammatory breast cancer if disease can be contained in radiotherapy portal)
•In select patients with operable breast cancer:
•a)HER2-positive disease and TNBC, if =cT2 or =cN1
•b)Large primary tumor relative to breast size in a patient who desires breast conservation.
•c)cN+ disease likely to become cN0 with preoperative systemic therapy.
•d)cT1c, cN0, HER2-positive disease and TNBC.
•2)Pathological evidence of breast cancer
•3)Informed consent for NACT signed by the patient
•4)Absence of Distant mets
•5)Age =18 years at the time of randomisation
•6)Performance status = 2

•1)Pregnancy or lactation
•2)Prior radiotherapy of the affected or contralateral breast
•3)Connective tissue disease, including rheumatoid arthritis and thromboangiitis obliterans
•4)Cardiac comorbidities: symptomatic coronary heart disease, prior heart attack, heart failure NYHA II or AHA C, pacemaker, and/or implanted defibrillator
•5)Other medical conditions that prohibit the neoadjuvant chemotherapy (i.e. psychiatric diseases, non-compliance, etc.)
•6)Patients with pure ductal carcinomas in situ.
•7)Patients with non-epithelial malignant conditions of the breast viz. Sarcomas, lymphomas, phyllodes tumors
•8)Synchronous primary

发起方

All India Institute of Medical Sciences, Jodhpur